Q1 EPS Estimates for Legend Biotech Cut by HC Wainwright

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Stock analysts at HC Wainwright decreased their Q1 2026 earnings estimates for shares of Legend Biotech in a research report issued to clients and investors on Monday, March 16th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.04) per share for the quarter, down from their previous estimate of $0.04. HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s FY2026 earnings at $0.42 EPS.

LEGN has been the subject of several other research reports. Truist Financial set a $70.00 target price on Legend Biotech in a research note on Tuesday, March 10th. Barclays cut their price target on Legend Biotech from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Wednesday, February 4th. Rothschild & Co Redburn cut Legend Biotech from a “buy” rating to a “neutral” rating and set a $24.00 price objective for the company. in a research report on Thursday, February 12th. UBS Group lowered their price objective on shares of Legend Biotech from $54.00 to $48.00 and set a “buy” rating on the stock in a research note on Monday, December 8th. Finally, Morgan Stanley cut their target price on shares of Legend Biotech from $50.00 to $49.00 and set an “overweight” rating for the company in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $58.31.

Legend Biotech Stock Performance

Shares of NASDAQ:LEGN opened at $17.87 on Thursday. The stock’s 50-day moving average is $19.10 and its 200-day moving average is $25.82. The company has a market cap of $3.30 billion, a P/E ratio of -22.34 and a beta of 0.07. Legend Biotech has a 52-week low of $16.24 and a 52-week high of $45.30.

Legend Biotech (NASDAQ:LEGN) last announced its earnings results on Tuesday, March 10th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.18. Legend Biotech had a negative net margin of 28.86% and a negative return on equity of 21.93%. The firm had revenue of $306.30 million for the quarter, compared to the consensus estimate of $310.21 million. During the same quarter last year, the firm posted $0.07 EPS. The business’s quarterly revenue was up 64.2% on a year-over-year basis.

Institutional Trading of Legend Biotech

A number of hedge funds have recently modified their holdings of the company. Clearstead Advisors LLC increased its position in shares of Legend Biotech by 76.5% during the third quarter. Clearstead Advisors LLC now owns 847 shares of the company’s stock valued at $28,000 after purchasing an additional 367 shares during the period. Parallel Advisors LLC raised its stake in shares of Legend Biotech by 171.9% in the third quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock valued at $34,000 after purchasing an additional 662 shares in the last quarter. OFI Invest Asset Management lifted its position in Legend Biotech by 102.6% in the third quarter. OFI Invest Asset Management now owns 1,228 shares of the company’s stock worth $40,000 after purchasing an additional 622 shares during the period. Raymond James Financial Inc. acquired a new stake in Legend Biotech during the second quarter worth $78,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Legend Biotech during the third quarter worth $104,000. Institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.